MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
CRBP - Corbus Pharmaceuticals Holdings Inc
$1.94
-0.03(-1.52%)8:59:54 PM 1/27/2021
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.
Stock Chart

Summary:

  • Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics

Peers

Stock news

    01/20/2021CRBP
    Corbus Pharmaceuticals Announces Presentations at the New York Academy of Sciences Webinar on Targeting the Endocannabinoid System to Treat Human Diseases

    Presentations about compounds in Corbus’ pipeline will highlight mechanistic studies of lenabasum, a CB2 agonist, and preclinical data from CB2 agonist oncology program and CB1 inverse agonist metabolism program Norwood, MA, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced it will participate in th...

    01/14/2021CRBP
    Corbus Pharmaceuticals (CRBP) Catches Eye: Stock Jumps 7.3%

    Corbus Pharmaceuticals (CRBP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

    01/12/2021CRBP
    Implied Volatility Surging for Corbus Pharmaceuticals (CRBP) Stock Options

    Investors need to pay close attention to Corbus Pharmaceuticals (CRBP) stock based on the movements in the options market lately.

    01/9/2021CRBP
    A Look At Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Share Price Returns

    While not a mind-blowing move, it is good to see that the Corbus Pharmaceuticals Holdings, Inc. ( NASDAQ:CRBP ) share...

    12/8/2020CRBP
    Is CRBP A Good Stock To Buy Now?

    The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]

    12/4/2020CRBP
    Are Options Traders Betting on a Big Move in Corbus (CRBP) Stock?

    Investors need to pay close attention to Corbus (CRBP) stock based on the movements in the options market lately.

    12/1/2020CRBP
    Looking Into Corbus Pharmaceuticals's Return On Capital Employed

    Corbus Pharmaceuticals (NASDAQ: CRBP) reported Q3 sales of $1.23 million. Earnings fell to a loss of $33.97 million, resulting in a 10.92% decrease from last quarter. Corbus Pharmaceuticals collected $286.35 thousand in revenue during Q2, but reported earnings showed a $38.14 million loss.Why ROCE Is Significant Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher R...

    11/16/2020CRBP
    ROCE Insights For Corbus Pharmaceuticals

    During Q3, Corbus Pharmaceuticals (NASDAQ: CRBP) brought in sales totaling $1.23 million. However, earnings decreased 10.92%, resulting in a loss of $33.97 million. Corbus Pharmaceuticals collected $286.35 thousand in revenue during Q2, but reported earnings showed a $38.14 million loss.What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. ...

    11/12/2020CRBP
    Corbus Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference

    * Fireside chat with live audio webcast on Thursday, November 19th at 12:35 PM EST Norwood, MA, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on ...

    11/11/2020CRBP
    Corbus Pharma Drops 6% On 3Q Miss; Street Sees 79% Upside

    Shares of Corbus Pharmaceuticals are down about 5.7% in pre-market trading on Wednesday after reporting lower-than-expected 3Q results. The pharma giant posted a loss of $0.43 per share, which was larger than the loss of $0.41 per share expected by analysts and compared to the year-ago loss of $0.32.3Q revenues of $1.23 million also missed the consensus estimates of $3.24 million and declined 52.5% year-over-year, due to “revenue recognized under the Cystic Fibrosis Program Related Investment Ag...